Escherichia coli Heat-Labile Enterotoxin B Limits T Cells Activation by Promoting Immature Dendritic Cells and Enhancing Regulatory T Cell Function. by Bignon, Alexandre et al.
May 2017 | Volume 8 | Article 5601
Original research
published: 15 May 2017
doi: 10.3389/fimmu.2017.00560
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Luis Graca, 
Universidade de 
Lisboa, Portugal
Reviewed by: 
Abdelhadi Saoudi, 
Institut national de la 
santé et de la recherche 
médicale (INSERM), France  
Bruce Milne Hall, 
University of New South 
Wales, Australia
*Correspondence:
Alexandre Bignon 
alexandre.bignon@babraham.ac.uk; 
Michelle A. Linterman 
michelle.linterman@babraham.ac.uk
Specialty section: 
This article was submitted to 
Immunological Tolerance 
and Regulation, 
a section of the journal 
Frontiers in Immunology
Received: 16 February 2017
Accepted: 26 April 2017
Published: 15 May 2017
Citation: 
Bignon A, Watt AP and 
Linterman MA (2017) Escherichia coli 
Heat-Labile Enterotoxin B Limits 
T Cells Activation by Promoting 
Immature Dendritic Cells 
and Enhancing Regulatory 
T Cell Function. 
Front. Immunol. 8:560. 
doi: 10.3389/fimmu.2017.00560
Escherichia coli heat-labile 
enterotoxin B limits T cells 
activation by Promoting immature
Dendritic cells and enhancing 
regulatory T cell Function
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Treatments to limit T cell activation are essential for managing autoimmune and inflamma-
tory disorders. The B subunit of Escherichia coli heat-labile enterotoxin (EtxB) is known 
to ameliorate inflammatory disease in vivo but the mechanism by which this is mediated 
is not well understood. Here, we show that following intranasal administration, EtxB acts 
on two key cellular regulators of T cell activation: regulatory T cells and dendritic cells 
(DCs). EtxB enhances the proliferation of lung regulatory T cells and doubles their sup-
pressive function, likely through an increase in expression of the Treg effector molecule 
CTLA-4. EtxB supports the generation of interleukin-10-producing DCs that are unable 
to activate T cells. These data show, for the first time, that mucosal EtxB treatment limits 
T cells activation by acting jointly on two distinct types of immune cells.
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inTrODUcTiOn
Robust immunological tolerance is essential to prevent development of autoimmune and autoin-
flammatory disorders. The challenge of the immune system is to balance potent effector mechanisms 
against foreign pathogens, while remaining unresponsive to self-antigens. The mucosal immune 
system faces a more complex challenge in that it must also regulate commensal microbial communi-
ties that are essential for health, in addition to discriminating between self- and non-self-antigens 
(1, 2). This balance is maintained by a number of cell types, including Foxp3+ regulatory T (Treg) cells 
and immature or tolerogenic dendritic cells (DCs) (3, 4). Treg cells are a population of suppressive 
CD4+ T cells that act to limit the effector functions of other leukocytes such as CD4+ T cells, thereby 
limiting inflammation and tissue damage. Within the mucosa, Treg cells modulate inflammatory 
responses by producing high levels of interleukin-10 (IL-10), restraining the generation of inflamma-
tory disease (5–7). Tolerogenic DCs are antigen-presenting cells that are thought to able to promote 
T cell tolerance to a defined antigen. Typically, tolerogenic DCs have an “immature” phenotype, 
expressing lower levels of the cell surface receptors that are required to activate T cells (8). In the 
lung, DCs remain in an immature state and fail to activate naïve T  cells, unless they receive an 
activating signal in parallel with antigen (9). However, whether a specific tolerogenic DC lineage 
exists in vivo or whether this is simply a modification of their activation status is unclear; because 
of this we will refer to these cells as immature DCs (10). Previous studies show that immature DCs 
may regulate immunological tolerance through different mechanisms such as the induction of T cell 
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anergy, generation of Treg cells and via production of IL-10 and 
transforming growth factor (TGF)-β (4, 11–13). In addition, 
immature DCs can support Treg cell differentiation in  vivo 
through presentation of low levels of antigen in major histocom-
patibility complex (MHC)-II (14–16). Therapeutic strategies that 
augment numbers and/or function of Treg cells, immature DCs, 
or both, represent a way to enhance mucosal tolerance by limiting 
T cell activation.
The Escherichia coli heat-labile enterotoxin is a hetero-
oligomeric AB5 toxin composed of a toxic enzymatic A subunit 
and five identical non-toxic B subunits (EtxB) (17). In the 
context of infection, the B subunit mediates cellular entry of the 
A subunit into the cytoplasm by binding to GM1 ganglioside 
receptor, which is ubiquitously expressed by all somatic cells 
(18). Several studies have demonstrated the immunomodula-
tory effects of EtxB, with emphasis on its adjuvant properties, 
although the mechanism by which EtxB act as an adjuvant is 
not yet known (19–22). Previous studies reported that recom-
binant EtxB is non-toxic and its effects are dependant on EtxB 
binding to cell surface receptors, as evidenced by a failure of 
a non-receptor-binding mutant, EtxB (G33D), to induce any 
immunomodulatory effects (23–27). At the cellular level, one 
study suggests that EtxB binding to GM1 receptor induces both 
caspase-dependent and -independent cell death pathway in 
CD8+ T cells (28). Conversely, a different study highlighted that 
receptor occupancy by EtxB on B cells is associated with main-
tenance of B-cell survival by activation of molecules essential 
for B-cell differentiation (29). Interestingly, binding of EtxB to 
GM1 receptor seems to be essential for EtxB-mediated antigen 
presentation by a immortalized murine bone marrow-derived 
dendritic cell (BMDC) line; however, EtxB did not induce 
maturation of BMDC (30, 31). At the molecular level, one study 
reported that receptor binding by EtxB triggers MAPK/ERK 
kinase activation in B cells (27). However, the precise molecular 
mechanisms by which EtxB induces direct or indirect effects on 
immune cells are largely unknown, in particular on DCs and 
Treg cells. Nevertheless, mucosal administration of EtxB amelio-
rates the disease severity of type 1 diabetes and collagen-induced 
arthritis in mice (23, 25). Treatment of these autoimmune mouse 
models with EtxB administration has been recapitulated by the 
transfer of splenocytes from EtxB-treated mice. Interestingly, 
when these splenocytes were devoid of CD4+ T cells they could 
not mediate tolerance, suggesting a role for EtxB in modulating 
suppressive Treg cells. In support of this model, intranasal (i.n.) 
administration of EtxB increased the frequency of Foxp3+ cells 
within the CD4+ T cell population (24, 26). Together, these stud-
ies suggest that EtxB supports tolerance through increasing Treg 
cell number. However, the mechanism by which EtxB does this 
has not been determined, nor is it known if EtxB can alter the 
suppressive capacity of Treg cells.
In addition, i.n. administration of EtxB induces IL-10 and 
TGF-β1 production by both epithelial cells in nasal-associated 
lymphoid tissue and CD11b+ cells in the cervical lymph nodes 
which suggest that EtxB may promote a tolerogenic environment 
(26). In vitro EtxB treatment increases viability of DCs and results 
in lower expression of MHC class II, CD80, and CD86 features 
of an immature phenotype (32). This suggests that in addition to 
enhancing Treg cell proportion, EtxB may also promote imma-
ture DCs in vivo, although this has not yet been demonstrated.
Interestingly, oral, nasal, or sublingual coadministration of the 
related non-toxic B subunit protein of cholera toxin (CTB) with 
selected antigens have been found to induce tolerance, including 
in autoimmune disorders and allergies in several animal models 
(33). One of the suggested mechanisms is that the coadministra-
tion of CTB with antigen results in increase of antigen-specific 
Foxp3+ Treg cells (33). In addition, CTB diminishes the respon-
siveness of macrophages and monocytes to lipopolysaccharide 
(LPS) (34).
Our study aimed to determine the mechanism by which EtxB 
treatment promotes the accumulation of Treg cells at mucosal 
sites and whether EtxB treatment affects Treg cell function and 
DC activation status and function. We confirm that i.n. EtxB treat-
ment increases the proportion of IL-10+ Foxp3+ Treg cells and, for 
the first time, show that this treatment increased the suppressive 
function of Treg cells, likely through increases in expression of 
the key Treg effector molecule CTLA-4 (cytotoxic T-lymphocyte-
associated protein 4). In addition, mucosal administration of 
EtxB also increases the frequency of CD8− cDCs with an imma-
ture phenotype and enhances their ability to produce IL-10. We 
show in vitro that EtxB directly promotes immature phenotype 
in BMDCs that fail to activate naïve CD4+ T cells. Together, these 
data demonstrate that EtxB alters the cellular composition of the 
lung, promoting a regulatory environment that is likely the cause 
of the anti-inflammatory activity of this protein.
MaTerials anD MeThODs
experimental animals
C57BL/6, TCR7 (35), and ITIB mice (36) (provided by H. Bouabe 
and K. Okkenhaug) were housed under specific pathogen-free 
conditions at the Biological Support Unit, Babraham Research 
Campus, Cambridge, UK. All experiments were approved by the 
UK Home Office under the UK Home Office license PPL 80/2526, 
in line with the Scientific Procedures Act (1986).
administration of etxB
EtxB-endotoxin free (Trident Pharmaceuticals, USA) was admin-
istered by the intranasal route under inhaled isoflurane anesthe-
sia. Each mouse was administered 100  µg EtxB (as previously 
described), or heat-inactivated EtxB (95°C for 10 min), in 20 µl of 
sterile PBS or 20 µl of sterile PBS alone, on three consecutive days 
(23). The dose of 100 µg EtxB used i.n. has previously been shown 
to promote tolerance (23). Mice were euthanized at different time 
points after the last treatment, as indicated in the figure legend.
Flow cytometry and cell sorting
Single-cell suspensions were prepared from mouse spleen by 
sieving and gentle pipetting through Falcon 70 µm nylon mesh 
filters (BD Biosciences, San Jose, CA, USA). To prepare cell 
suspensions from mediastinal lymph node (mLN), the tissue 
was incubated with 1 mg/ml Collagenase D (Roche Diagnostics, 
Mannheim, Germany), and 400 U/ml DNase I (Sigma-Aldrich, 
St. Louis, MO, USA) for 20 min at room temperature, followed by 
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gentle pipetting to disrupt tissue. Lung lymphocytes were isolated 
by finely mincing the lung tissues and digesting with 2  mg/ml 
Collagenase (Sigma-Aldrich, St. Louis, MO, USA) and 0.2 mg/ml 
DNase I (Roche Diagnostics) at 37°C for 30  min, followed 
by sieving and gentle pipetting through Falcon 70  µm nylon 
mesh filters (BD Biosciences). Red blood cells were removed by 
using ammonium chloride lysis buffer. Cells were washed with 
PBS with 2% FCS, (PBS–FCS 2%) then stained with antibody 
cocktails. Different gating strategies were used to define myeloid 
and common DC subsets as previously described (32) (Figure 
S2 in Supplementary Material). For intracellular staining, cell 
suspensions were fixed and permeabilized using the Intracellular 
Fixation and Permeabilization Buffer Set as per the manufacturer’s 
instructions (eBioscience, San Diego, CA, USA). Annexin V and 
DAPI staining procedure was performed following Annexin V 
Staining Protocol from BD Biosciences. To assess IL-10 produc-
tion ex vivo, we used IL-10-β-lactamase reporter mice (ITIB) (36) 
as described previously. Briefly, IL-10 was detected in cells from 
ITIB mice using CCF4-AM staining solution supplemented with 
probenecid, prepared according to the manufacturer’s instruc-
tions (Thermo Scientific, Wilmington, DE, USA), and incubated 
for 75 min at room temperature. Cells were washed with PBS–FCS 
2% and analyzed by flow cytometry. For cell sorting, conven-
tional naïve CD4+ T cells (B220−CD3+CD4+CD25−CD62L+) or 
regulatory T cells (B220−CD3+CD4+CD25+) were sorted from the 
spleen or the lung, respectively, after cell surface staining. FACS 
was performed with a FACSAria cell sorter (BD Biosciences) and 
sorted populations were between 95 and 99% purity. Analyses 
were carried out on an LSR Fortessa (BD Biosciences) using 
FlowJo software (TreeStar, Ashand, OR, USA).
antibodies and Dyes for Flow cytometry
Antibodies for flow cytometry were from eBioscience except 
where otherwise indicated: anti-CD4 (Biolegend, London, UK, 
RM4-5), anti-CD8 (Becton Dickinson, 53-6.7), anti-Foxp3 
(FJK-16S), anti-Ki-67 (SolA15), anti-CTLA-4 (UC10-4B01), anti-
CD304 (3DS304M), anti-CD25 (PC61.5), anti-CD80 (16-10A1), 
anti-CD86 (GL1), anti-CD11b (M1/70), anti-CD11c (N418), 
anti-MHC-II (M5/114.15.2), anti-CD69 (H1.2F3), Annexin V, 
and DAPI.
regulatory T cell suppression assay
Regulatory T cell suppression assay was performed as previously 
published (37). Briefly, conventional splenic CD4+ T cells were 
isolated from untreated C57BL/6 mice and labeled with 10 µM 
CellTrace Violet (eBioscience). Conventional CD4+ T  cells 
(2.5 × 104/well) were activated with anti-CD3 anti-CD28 coated 
beads (Gibco by Life Technologies, AR, Oslo) and cultured either 
alone or with lung CD4+CD25+ regulatory T  cells at a range 
of ratios from 1:1 to 64:1 (CD4+CD25−: CD4+CD25+). After 
4  days of culture, proliferation of conventional CD4+ T  cells 
was determined by CellTrace violet dilution by flow cytometry 
and the percentage of suppression of CD4+CD25+ T  cells can 
be calculated using the following formula: [(% of proliferation 
of CD4+CD25− cells alone − % of proliferation of CD4+CD25− 
treated with CD4+CD25+)/% of proliferation of CD4+CD25− cells 
alone] as previously described (37).
BMDc culture and Treatment
Bone marrow cells were obtained from the femur and tibia of 
untreated C57BL/6 mice (38). To generate BMDCs, the cells were 
cultured in RPMI-1640 medium supplemented with 10% FCS, 
20 ng/ml of GM-CSF (R&D systems, Abingdon, UK), 10 ng/ml 
of IL-4 (R&D systems) and 50 µM of 2-Mercaptoethanol (Sigma-
Aldrich) for 6 days. To induce activation, BMDCs were treated 
with 1 mg/ml of LPS (Sigma-Aldrich) for three additional days 
of culture. To generate tolerogenic DC, bone marrow cells were 
cultured in RPMI-1640 medium supplemented with 10% FCS, 
20 ng/ml of GM-CSF, 20 ng/ml of IL-10, 20 ng/ml of TGF-β (R&D 
systems), and 50  µM of 2-Mercaptoethanol for 9  days. BMDC 
cells were cultured for 12 h with hEtxB or EtxB (both at 10 µg/
ml) at 37°C in 5% CO2. The concentration of hEtxB or EtxB used 
in vitro and the time of treatment was consistent with previously 
published studies (32).
antigen-specific Presentation assay
Hen egg lysozyme (HEL) or ovalbumin (OVA) (Sigma-Aldrich) 
were added to BMDCs at 1 mg/ml for 24 h, cells were fixed in 
0.75% paraformaldehyde for 30 min on ice. Naïve TCR7 CD4+ 
T  cells were isolated using a MagniSort™ Mouse CD4 Naïve 
T cell Enrichment Kit (eBioscience) according to the manufac-
turer’s instructions. 9 × 104 BMDCs that were exposed to HEL 
or OVA were co-cultured with 2.5 × 105 naïve CD4+ transgenic 
T cells in RPMI-1640 containing 5% FCS (Fixed BMDCs:CD4+ 
T cells = 1:3). CD4+ T cell activation was assessed by flow cytom-
etry at 5 h post co-culture by membrane expression of CD69.
statistics
Data are presented as mean ± SD. Single comparisons were ana-
lyzed using the non-parametric Mann–Whitney U-test. All statis-
tical analyses were carried out with GraphPad Prism v6 (La Jolla, 
CA, USA).
resUlTs
The Proportion of Foxp3+ regulatory  
T cells increase Following intranasal  
etxB Treatment
Foxp3+ Treg cells are powerful mediators of immunological 
tolerance; their frequency has been reported to increase upon 
EtxB treatment (24, 26). We first sought to confirm this follow-
ing i.n. EtxB administration. In the lung, EtxB treatment results 
in an increased proportion of CD4+ T  cells expressing Foxp3 
2.5  days after treatment (Figures  1A,B) compared to control 
mice that received PBS or biologically inactive heat-treated EtxB 
(hEtxB). By contrast, the increased frequency of Treg cells is not 
detectable 2.5 days posttreatment in the draining mLN or spleen 
(Figure  1B). Interestingly, an increased proportion of Tregs in 
the spleen is detectable at day 9 posttreatment (Figure S1A in 
Supplementary Material), suggesting that the mucosal site of 
administration is the first and major location of EtxB action on 
Treg cells. Interestingly, no differences in the spleen, the mLN, or 
in the lung were observed between PBS- and hEtxB-treated mice 
at day 2.5 following treatment indicating that hEtxB is a relevant 
FigUre 1 | intranasal treatment of etxB increases the proliferation of Treg cells. C57BL/6 mice were administered, EtxB (100 μg/mouse), heat inactivated 
EtxB (hEtxB, 100 μg/mouse) or PBS on three consecutive days. On day 2.5 following the last dose, spleen, mediastinal lymph node, and lung were removed and 
analyzed by flow cytometry. Flow cytometric contour plots (a) and dot plots (B) show the frequency of Foxp3+ regulatory T (Treg) cells in CD4+ B220− cells. The 
frequency of Ki67+ proliferating Treg cells or CD4+ Foxp3− T cells (c,D) and frequency of live (Annexin V− DAPI−) CD4+ CD25+ cells (e,F) in the lung. Results are from 
one experiment representative of three independent experiments, with six mice per group. In dot plots, the mean and SD are represented and each circle represents 
one mouse: white squares PBS treated animals, white dots hEtxB-treated animals, black dots EtxB-treated animals. *p < 0.05 and **p < 0.005 compared with 
PBS- or hEtxB-treated mice (Mann–Whitney U-test).
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biologically inactive negative control (Figure 1B). While previous 
studies have reported an increase in Treg cell proportion follow-
ing EtxB treatment, they have not determined how this occurs. 
This observation suggests that EtxB may be able to alter Treg cell 
proliferation and/or survival. To test this, we determined the fre-
quency of proliferating (Ki67+) and live (Annexin V−DAPI−) Treg 
cells in the lung 2.5 days after EtxB administration. After EtxB 
treatment, Treg cells had a significantly increased proportion of 
both Ki67+ cells (Figures 1C,D) and live cells (Figures 1E,F). By 
contrast, EtxB administration is not able to induce the prolifera-
tion of CD4+ Foxp3− T cells suggesting an EtxB-Treg specific effect 
and that EtxB alone seems not to be “immunogenic” on naïve/
effector CD4+ T cells (Figure 1D). Together, the increase in cell 
proliferation with a decrease in cell death likely accounts for the 
higher proportion of Treg cells in the lung of EtxB-treated mice 
and that mucosal sites are the principle location of this effect.
The suppressive Function of Treg cells  
is enhanced by etxB Treatment
Previous work has suggested that EtxB dampens inflammation 
through increased proportion of Treg cells (23–25), but it is also 
possible that EtxB functionally alters Treg cells. We sought to 
determine if mucosal administration of EtxB alters the activation 
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status and/or suppressive capacity of Treg cells. CTLA-4 is a key 
effector molecule for Treg cell function (39); Treg cells from EtxB-
treated mice had increased expression of CTLA-4 compared 
to control hEtxB-treated mice in the lung, but the expression 
is unchanged in the mLN (Figures  2A,B and Figures S1B,C 
in Supplementary Material). In the lung, the expression of 
Neuropilin-1 on Treg cells is not affected in EtxB-treated mice 
suggesting no preferentially effect of EtxB on thymic Treg cells 
or induced peripheral regulatory T cells (Figures 2C,D). Several 
studies have shown that IL-10 plays a role in Treg cell suppres-
sive function at mucosal sites (40, 41). To investigate the effect 
of i.n. EtxB administration on IL-10 production by Treg cells in 
the lung, we used an IL-10-β-lactamase (ITIB) reporter mouse 
(36). Treatment with EtxB resulted in a twofold increase in the 
frequency of IL-10-producing Treg cells, compared to control 
hEtxB-treated mice (Figures  2E,F). Interestingly, EtxB did not 
alter expression of other markers of Treg induction/activation 
such as inducible T-cell costimulator, programmed cell death 
1, CD101, and CD103 (data not shown). Together, increased 
CTLA-4 and IL-10 expression suggests that EtxB is able to enhance 
the functional capacity of Treg cells. To test this hypothesis, we 
performed an in vitro Treg suppression assay (37). CD4+CD25+ 
Treg cells were isolated from the lung of EtxB-treated C57BL/6 
mice by flow cytometric cell sorting and co-cultured with naïve 
CD4+ T cells from an untreated animal, and the ability of Treg 
cells to suppress TCR-driven CD4+ T  cell proliferation was 
assessed. CD4+CD25+ Treg cells taken from EtxB-treated mice 
had twice the suppressive function of Treg cells isolated from 
hEtxB-treated control animals (Figures  2G,H). These findings 
demonstrate that mucosal administration of EtxB enhances the 
suppressive function of Treg cells, describing a novel role for EtxB 
in modifying Treg cell biology.
Mucosal etxB administration increases 
immature Dcs
ExtB has previously been shown to modify innate cells, by 
reducing the frequency of DC precursors and myeloid precur-
sors in secondary lymphoid tissues (32), and by increasing the 
expression of IL-10 and TGF-β transcripts in CD11b+ cells (26). 
To confirm that EtxB acts on innate cells at mucosal sites, we 
examined the effect of i.n. EtxB administration on lung dendritic 
and myeloid cell subsets (Figure S2 in Supplementary Material). 
Consistent with the previous report (32), EtxB treatment reduced 
the proportion of conventional DC precursors (pre-cDC, 
CD11clowCD11b+CD8−MHC-II−) and myeloid cell precursors 
(CD11b+CD11c−CD8−MHC-II−) in the lung (Figures S3A,B 
in Supplementary Material). In addition, we also observed that 
expression of CD80 was upregulated in plasmacytoid pre-DCs 
(p-preDC, CD11clowCD11b−CD8−MHC-II−), pre-cDC, and 
myeloid precursors, while CD86 was elevated in pre-cDC in 
the lung of EtxB-treated mice (Figures S3C,D in Supplementary 
Material). In the mLN, EtxB treatment reduced only the propor-
tion of myeloid cell precursors (Figures S4A,B in Supplementary 
Material) and had no effect on the expression of CD80 or CD86 
in dendritic and myeloid cell precursors (Figures S4C,D in 
Supplementary Material). This suggests that EtxB can alter both 
the proportion and phenotype of innate immune cells in the lung 
and mLN.
Next, we investigated the effect of i.n. EtxB administration on 
mature DC subsets; plasmacytoid DC (pDC, CD11clow CD11b− 
CD8−MHC-II+), CD8−, and CD8+ cDCs (CD11chighCD11b+ 
CD8−/+MHC-II+) in the lung and in the mLN. The proportions 
of these DC subsets were not affected by i.n. EtxB administra-
tion in either organ (Figures  3A–C). But, we observed that 
CD8−cDC and pDC from EtxB-treated mice have significantly 
reduced expression of MHC class II, consistent with a profile of 
“immature” DCs (Figures 4A–C). The low levels of MHC class 
II on DCs from EtxB-treated mice is intriguing in the context 
of immunological tolerance, as DCs of this phenotype have 
also been described to have a poor capacity to activate T cells. 
Interestingly, the inability of immature DCs to activate T  cells 
is partially dependent on IL-10 production by immature DCs 
(13, 16, 42). To investigate the ability of EtxB to promote IL-10 
production by these immature phenotype DCs, we treated ITIB 
mice with EtxB or hEtxB as a control. EtxB-treated mice had a sig-
nificantly increased percentage of IL-10+ CD8−cDC compared to 
hEtxB-treated control mice (Figures 4D,E). We did not observe 
any effect of EtxB treatment on IL-10 expression by the other 
subsets of DCs or myeloid cells (data not shown). These results 
show that mucosal administration of EtxB increases the propor-
tion of “immature” IL-10+ CD8− cDCs, a new immunoregulatory 
mechanism by which EtxB can modify the innate immune system 
at the mucosal surface.
etxB induces immature BMDcs That  
are Unable to activate T cells In Vitro
These data prompt the hypothesis that EtxB treatment results 
in an increase of immature DC population that fail to induce 
T cell activation, which may partly explain the regulatory effects 
of EtxB in  vivo. To test this, we assessed the effect of EtxB on 
in vitro generated CD11b+ CD11c+ BMDCs. Bone marrow cells 
from C57BL/6 mice were cultured with GM-CSF and IL-4 (38) 
for 6  days prior to treatment with either RPMI alone or with 
hEtxB or EtxB followed by analysis of MHC class II expression 
(Figure  5A). As a positive control, we treated BMDCs with 
LPS to induce activation, leading to MHC-II upregulation. As 
a negative control, we generated BMDCs in tolerogenic culture 
conditions (with IL-10 and TGF-β), which reduced expression 
of MHC class II (38). EtxB treatment resulted in BMDCs that 
expressed a lower level of MHC class II compared to control 
cells. EtxB-treated BMDCs phenotypically resembled in  vitro-
induced immature BMDCs (Figures  5B,C). This suggests that 
EtxB can act directly on BMDCs to reduce expression of MHC 
class II and directly promotes an immature state thereby imped-
ing their capacity to activate T cells. To test this, we performed 
an in  vitro T  cell activation assay with naive TCR7 transgenic 
CD4+ T cells specific for the subdominant H-2b epitope of HEL. 
LPS-, IL-10-, hEtxB-, or EtxB-treated BMDCs were exposed to 
1 mg/ml of HEL, or OVA antigen as negative control, for 24 h. 
The cells were washed, fixed, and added at a ratio 1:3 to TCR7 
cells. Fixation was performed to ensure that the BMDCs did not 
mature during culture with T cells (43). Incubation of BMDCs 
FigUre 2 | continued
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FigUre 3 | etxB does not alter mature dendritic cell (Dc) subsets. C57BL/6 mice were treated intranasally with 100 μg/mouse EtxB or heat-EtxB (hEtxB) for 
3 days. On day 2.5 posttreatment, lung and mediastinal lymph node (mLN) were removed and analyzed, flow cytometric contour plots (a) and dot plots show the 
proportion of DCs subsets in the lung (B) and mLN (c). Subsets of DC include plasmacytoid DC (pDC, CD11clowCD11b−CD8−MHC-II+), CD8− and CD8+ 
conventional DCs (CD8+ or CD8− cDC, CD11chighCD11b+CD8−/+ MHC-II+). Results are from one experiment representative of six mice in each group from three 
independent experiments In dot plots, the mean and SD are represented and each circle represents one mouse: white dots hEtxB-treated animals, black dots 
EtxB-treated animals.
FigUre 2 | continued  
etxB increases the suppressive function of Treg cells. Expression of CTLA-4 (a,B) or Neuropilin-1 (c,D) on lung B220− CD4+ Foxp3+ Treg cells from C57BL/6 
mice treated intranasally with 100 μg/mouse EtxB or heat-EtxB (hEtxB) for three consecutive days, and analyzed by flow cytometry at 2.5 days after the final 
treatment. (e,F) Intranasal administration of 100 μg/mouse EtxB or hEtxB to ITIB mice. Day 2.5 posttreatment, lungs were removed and analyzed by flow cytometry 
for the proportion of IL-10+ (CCF-4 blue) in B220− CD4+ Foxp3+ Treg cells. (g,h) Groups of 10 C57BL/6 mice were treated intranasally with 100 μg/mouse EtxB or 
hEtxB for three consecutive days. On day 2.5 posttreatment, lungs were removed and CD4+ CD25+ Treg cells were flow sorted and were co-cultured with splenic 
CD4+ CD25− T cells isolated from untreated C57BL/6 mice that have been labeled with CellTrace Violet. Cells were cultured at the ratio of CD4+CD25−: CD4+CD25+ 
indicated on the graph. After 4 days, proliferation was determined by CellTrace Violet dilution (e) and the percentage of suppression of CD4+ CD25+ T cells was 
assessed using the following formula: [(% of proliferation of CD4+CD25− cells alone − % of proliferation of CD4+CD25− treated with CD4+CD25+)/% of proliferation  
of CD4+CD25− cells alone] as previously described (37). Results are from one experiment representative of six (a–D) or four (e,F) mice in each group from three 
independent experiments. In histograms (a,c), the shaded area represents the fluorescence minus one control. In dot plots, the mean and SD are represented and 
each circle represents one mouse: white dots hEtxB-treated animals, black dots EtxB-treated animals. Results in (g,h) are from one experiment representative of 
three independent experiments. *p < 0.05 and **p < 0.005 compared with hEtxB-treated mice (Mann–Whitney U-test).
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with HEL or OVA had no effect on MHC class II, CD80 and 
CD86 membrane expression (data not shown). As expected, in 
all conditions, BMDCs exposed to OVA antigen were unable to 
induce expression of the early activation marker, CD69, on TCR7 
CD4+ T cells (Figures 5D,E). BMDCs pulsed with HEL and acti-
vated with LPS were able to induce CD69 expression on T cells, 
while IL-10-induced BMDCs were not (Figures 5D,E). We found 
that HEL-pulsed hEtxB-BMDCs stimulated CD69 expression 
FigUre 4 | continued
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FigUre 4 | continued  
etxB promotes immature dendritic cells (Dcs). C57BL/6 mice were treated intranasally with 100 μg/mouse EtxB or heat-EtxB (hEtxB) for 3 days. On day 2.5 
posttreatment, lung and mediastinal lymph node (mLN) were removed and analyzed. Flow cytometric histograms (a) and dot plots of membrane expression of 
major histocompatibility complex (MHC) class II on plasmacytoid DC (pDC, CD11clowCD11b−CD8−MHC-II+), CD8−, and CD8+ conventional DCs (CD8+ or CD8− cDC, 
CD11chighCD11b+CD8−/+ MHC-II+) in the lung (B) and mLN (c). ITIB mice were administered either 100 μg/mouse EtxB or hEtxB for 3 days. Flow cytometric contour 
plots (D) and dot plots (e) represent the frequencies of IL-10+ (CCF4-blue) CD8− cDC cells in the lung 1 day posttreatment. In panel (a–c), results are from one 
experiment representative of six C57BL/6 mice per group from three independent experiments. In (D,e), results are from one experiment representative of four ITIB 
per group from two independent experiments. In dot plots, the mean and SD are represented and each circle represents one mouse: white dots hEtxB-treated 
animals, black dots EtxB-treated animals. *p < 0.05 and **p < 0.005 compared with hEtxB-treated mice (Mann–Whitney U-test).
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on transgenic T cells, but that BMDCs treated with EtxB were 
unable to induce T cell expression of CD69 above background 
levels (Figures 5D,E). Overall, these findings indicate that EtxB 
directly promotes in vitro “immature” BMDCs that fail to activate 
naïve CD4+ T cells.
DiscUssiOn
EtxB has been shown to ameliorate immune pathology in numer-
ous mouse models of inflammatory disease (23–25). However, 
the way EtxB alters the immune system to mediate these effects 
has not been fully elucidated. Here, we show that EtxB acts 
directly at mucosal sites to increase the proportion and function 
of suppressive Treg cells and to promote CD8− cDCs with an 
immature phenotype. Importantly, EtxB is able to act directly on 
BMDCs to promote immature antigen-presenting cells that do 
not have the capacity to activate naïve CD4+ T cells. Together, 
these data indicate that the immunoregulatory effects of EtxB 
work by increasing the frequency of leukocytes that promote tol-
erance, and further modulating their function to dampen T cell 
activation.
Our results build substantially on previous studies indicat-
ing that i.n. administration of EtxB increased the frequency of 
Foxp3+ Treg cells (24, 26). In our study, we confirm that EtxB 
increases Treg proportion and show that this occurs rapidly and 
preferentially in mucosal tissues. The data show that the likely 
cause of increased Treg cell frequency following EtxB treatment 
is due to increased proliferation of thymic-derived Treg cells, 
with a concomitant decrease in cell death. While the molecular 
mechanism behind this cellular phenotype is unknown, studies 
on other cell types may provide some insight into the potential 
cause. It has been reported that EtxB–receptor interaction on 
B  cells leads to induction of phosphatidylinositol-3 kinase 
(PI3-kinase)-dependent signaling cascades that regulate B  cell 
activation (27). Because of the central role of PI3-kinase in cell 
growth, differentiation, survival and proliferation in T cells, and 
important role in Treg cell function (44), one can speculate that a 
mechanism dependent on PI3-kinase activation could contribute 
to increase proliferation and survival of Treg cells driven by EtxB.
Our results demonstrate that mucosal administration of EtxB 
promotes Tregs cells with a greater suppressive capacity. There 
are numerous mechanisms used by Tregs cell to impart suppres-
sion, including production of inhibitory cytokines (TGF-β, IL-10, 
IL-35), inhibitory receptors (CTLA-4, lymphocyte-activation 
gene 3), cytotoxicity (Granzyme/Perforin) and metabolic disrup-
tion (IL-2 deprivation-mediated apoptosis) (45). Blockade of 
CTLA-4 results in autoimmune disease and colitis in normal mice 
(46, 47), exacerbates diabetes in diabetes-prone non-obese mice 
(48), and abrogates Treg cell-mediated suppression (47, 49). 
Although, previous works suggested that the Treg cells that develop 
in absence of CTLA-4 have acquired compensatory suppressive 
mechanisms through enhanced TGF-β- or IL-10-dependent 
pathways (49, 50), one study revealed a non-redundant role for 
CTLA-4 expression by Treg cells to limit lymphopenia-induced 
CD4 T-cell expansion in vivo, which seems to be independent of 
IL-10, IL-35, TGF-β, or IDO (51). However, despite the important 
role of CTLA-4 for suppressive capacity, IL-10 is also important 
for Treg function, particularly at mucosal surfaces (52). Here, we 
observe that EtxB administration increases expression of IL-10 by 
Treg cells and we show that EtxB treatment results in increased in 
CTLA-4 expression. This results in enhanced functional capacity 
of Treg cells from EtxB-treated mice.
It has been previously demonstrated that EtxB treatment 
alters the innate immune system by reducing the proportion of 
precursors of cDCs and myeloid cells (32). Our work confirms 
this result in the lung and further shows that surface expression 
of the costimulatory ligand CD80 is upregulated on these cells. 
DCs are sentinels of the immune system and play an essential role 
in the maintenance of immune tolerance (14, 53). The potential 
of DCs to induce regulatory responses could be directly related 
to their maturation status (54). T cell inactivation in the lung can 
be induced by immature DCs that express low surface levels of 
MHC class II and costimulatory ligands. Notably, immature DCs 
are characterized by increased expression of programmed death-
ligand 1, decreased expression of MHC class II, and decreased 
expression of costimulatory molecules (such as CD86 or CD40) 
(55–57). These “immature” DCs have the capacity to induce or 
expand Tregs cells (14). We observed that lung CD8−cDC and pDC 
have significantly reduced membrane expression of MHC class 
II after EtxB treatment, consistent with an immature phenotype. 
In addition, we show that EtxB-treated mice had a significantly 
increased percentage of IL-10+ CD8−cDC in the lung compared to 
hEtxB-treated mice. Taken together, this suggests that following 
mucosal EtxB administration, the DCs with an immature phe-
notype are promoted; further, these cells produce IL-10 locally 
that may play a role in the establishment of an immunoregulatory 
microenvironment in the lung. In the mLN, EtxB treatment has 
no effect on Treg cells and DCs precursors at day 2.5 following 
i.n. administration. However, we observed increase proportion 
of immature CD8−cDC and pDC. Interestingly, although expres-
sion of CCR7 is considered an indicator of activated DCs, some 
“immature” DCs in peripheral tissues such as the lung can also 
up regulate CCR7, which allows them to migrate to the secondary 
lymphoid organs (58).
FigUre 5 | etxB inhibits the T cell activation capacity of bone marrow-derived dendritic cells (BMDcs) in vitro. BMDCs were induced by culturing bone 
marrow cells of C57BL/6 mice cultured with GM-CSF, IL-4 and 2-Mercaptoethanol for 6 days. (a) Flow cytometric contour plot of CD11b/CD11c expression on 
BMDC cultures. (B,c) Membrane expression of major histocompatibility complex (MHC) class II on BMDC cultures from different conditions as indicated, BMDCs 
were defined as CD11b+ CD11c+ cells. (D) Flow cytometric contour plots and bar chart (e) of CD69 expression on naïve TCR7 CD4+ T cells co-cultured with 
BMDCs generated under the indicated conditions, pulsed with either hen egg lysozyme (HEL) or ovalbumin (OVA) protein and then fixed. In dot plots, the mean and 
SD are represented and each symbol represents a technical replicate: white squares RPMI only treated cells, white circles hEtxB-treated cells, black circles 
EtxB-treated cells, white triangles interleukin-10 (IL-10)-induced tolerogenic BMDCs, black triangle lipopolysaccharide (LPS) treated BMDCs. In the bar chart, the 
height of the bar represents the mean; the error bars the SD. Results are from one experiment representative of three independent experiments. *p < 0.05 and 
***p < 0.0005 (Mann–Whitney U-test).
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In this study, we have addressed the question of how adminis-
tration of EtxB induces an immunoregulatory microenvironment 
in the lung. Our results suggest that EtxB is able to promote Treg 
cells and “immature” DCs. In both cases, there is a marked increase 
in IL-10 production. Interestingly, IL-10 is able to support the 
induction of both immature DCs and Treg cells (14, 59). Previous 
studies have shown increased expression of Il10 transcript 
in epithelial cells and CD11b+ cells following EtxB treatment 
(25, 26). Taken together, IL-10 production after EtxB administra-
tion is likely one of the key mechanisms supporting the increase 
in Treg cells and immature DCs. Interestingly, ERK1/2 pathway 
is one of the signaling cascades that is activated in macrophages 
and DCs that results in IL-10 expression (60). Of note, Polumuri 
et al shown that TLR4 engagement in murine innate cells activates 
the PI3-kinase/Akt pathway and promotes IL-10 production that 
is reversed by PI3-kinase inhibition (61). Because EtxB induces 
PI3-kinase and MAPK/ERK kinase signaling cascades in B cells, 
it would be interesting to assess the potential link between theses 
pathways and IL-10 production in Treg and DCs following EtxB 
administration. Also, how EtxB directly or indirectly promotes 
Treg cells and immature DCs able to produce IL-10 warrants 
further study.
Taken together, our study demonstrates that EtxB exerts its 
effects in vivo mainly at mucosal surfaces. It limits T cell activa-
tion through two mechanisms: first through increasing “imma-
ture” IL-10+ DCs that cannot activate T cells and second through 
increasing the proportion and function of Treg cells that limit 
T cell expansion. This model of EtxB action could explain why 
mucosal administration of EtxB protects from different T  cell-
dependent autoimmune diseases (23, 25) and suggests mucosal 
administration of EtxB as attractive therapeutic treatment for 
inflammatory disorders.
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